Clear Labels Act Reaches Full Senate Vote After Unique Facility Identifier and One-Year Timeline Are Struck
核心洞察
The Clear Labels Act (搜索), which would show where a drug was manufactured on its label, is headed to a full Senate vote after passing committee in July with only Sen. Rand Paul dissenting.
Senators removed the requirement to print a DUNS facility identifier on labels and extended the compliance timeline from one year to five years.
Safety experts including former FDA inspector Peter Baker say the changes will make the law harder to enforce and leave labels no more informative than today.
Landmark legislation intended to tell doctors and patients where their medicines are made is headed for a full Senate vote, but drug safety experts say the Clear Labels Act (搜索) has been stripped of two of its most critical provisions. The bill, introduced earlier this year by Sens. Rick Scott, R-Fla., and Kirsten Gillibrand, D-N.Y., passed the Senate Committee on Health, Education, Labor and Pensions in July with only Sen. Rand Paul, R-Ky., dissenting. A date for the full Senate vote has not been scheduled.
The legislation followed a ProPublica (搜索) investigation last year that found the U.S. continued importing generic drugs (搜索) from foreign factories after inspectors had identified quality and safety lapses at the sites, including leaks, mold and contaminated water. Medications made at those facilities were linked to thousands of reported adverse reactions in patients.
What the Bill Was Meant to Do
Current generic drug labels often list only the location of the packager or distributor, which can be thousands of miles from the actual manufacturer. The Clear Labels Act (搜索) aims to let doctors and patients see on the label exactly where a medication was made, details that had largely been withheld until now, even from Congress.
Two elements gave the bill its strength, according to experts. The label was to carry a unique code the Food and Drug Administration (搜索) uses to identify factories, which would have made it easier for researchers and the public to track the regulatory histories of specific facilities. The requirements were also to take effect as early as one year after passage.
Senators have now struck both provisions. People familiar with the deliberations said lawmakers worried the requirements would raise drug prices and weaken national security by revealing the precise locations where lifesaving medications are made. The unique identifier requirement has been removed, and the compliance timeline has been extended to five years.
Experts Question the Five-Year Window
"It's just a clear watering down of the original bill," said retired Army Col. Vic Suarez, a former medical supply-chain commander who has been leading a push for more domestic pharmaceutical manufacturing.
"It's just a clear watering down of the original bill," said retired Army Col. Vic Suarez, a former medical supply-chain commander who has been leading a push for more domestic pharmaceutical manufacturing.
A representative from Gillibrand's office said the five-year delay is meant to give the FDA time for rulemaking, which is a complicated, often yearslong process used to introduce new regulations, and to give manufacturers time to come into compliance and redesign their labels. Peter Baker, a former FDA inspector whose work involved the very companies impacted by the bill, disputed that justification.
"If they wanted to do it in one year, they could," Baker said. "I would love to hear their justification on why they need five years to develop some rules and guidance on transparency. I mean, it's a simple label change."
Dr. Kevin Schulman, a professor of medicine and health policy at Stanford University who has researched the economic pressures that lead to poor-quality generic drugs (搜索), also questioned the delay. "Five years after it passes might as well be a lifetime," he said. "Why is it that the supply chain, the medical distributors and the retailers don't want to make sure that they supply the highest-quality product?"
In a joint press release, Scott and Gillibrand praised the bill's progress in the Senate, calling it a "massive win for consumer safety and transparency," but did not address the changes.
Tracing a Drug Without the DUNS Number
The removed identifier is a DUNS number, a unique facility identification number that would have allowed the public to trace a generic drug and its active ingredients to the factories where they were made. In some cases, that identifier could also be used to find FDA inspection reports describing contamination and other safety breakdowns on factory floors.
ProPublica (搜索) used the ID number to build Rx Inspector (搜索), a first-of-its-kind tool that lets consumers and doctors look up where more than 40,000 generic drugs (搜索) are made. Pharmacists and patients are already using the tool to learn more about the drugs they take and prescribe.
Under the bill's updated language, labels will only be required to include factory addresses, which can be inconsistent and hard to trace to a manufacturing facility. A single address in India, for example, can house multiple factories, each producing its own drugs, or each with a slight variation on the same address.
ProPublica (搜索) reporters encountered this problem while collecting data for Rx Inspector (搜索). In 69% of prescription drug labels, reporters found a generic drug manufacturer's DUNS number and could directly connect it to a specific facility. When only a manufacturer's address was available, linking a drug to a particular facility became much harder, requiring automated address verification, geolocation and extensive manual review.
The "Place of Business" Loophole
Experts also flagged language in the legislation that could let manufacturers avoid identifying where their factories are at all. Representatives for the bill's sponsors have said manufacturers are required to identify the factory where drugs were made, but the legislation only mentions a "place of business." Drugmakers could potentially list the address of their headquarters or a U.S. subsidiary rather than a factory overseas.
"If, in fact, 'place of business' can be interpreted as the location of the importer or the headquarters or something like that, it would be no different than what we have today," said John Gray, an Ohio State University professor who testified before the Senate Special Committee on Aging, led by Scott and Gillibrand.
"Then we'll be right back to where we are," Gray said. "It'll say 'Manufactured for So-and-So in New York City,' but it's actually made somewhere else around the world."
People familiar with negotiations over the bill's language said they are confident manufacturers will not have a loophole. The changes were primarily a compromise between committee offices and stakeholders, they said, and the FDA will have final say in what counts as an acceptable address. Congress will work with the FDA to ensure the law is properly interpreted and enforced, according to those familiar with the negotiations.
Enforcement and Industry Pushback
Baker said the burden of ensuring compliance will fall to already-overworked inspectors, who will have to determine whether manufacturers are skirting the address requirement. Requiring the unique identifier would have been easier, he said, because inspectors could more readily verify the information.
"The more flexibility they allow, the more complex it is to enforce it," Baker said.
Baker also pushed back against national security concerns, saying data about where U.S. drugs come from is already well known and that including factory information on labels would not pose a significant risk. "It's a public health concern over a national security concern," he said. "I would say that those risks outweigh the national security concerns."
The Association for Accessible Medicines (搜索), the generic drug lobbying group, did not respond to multiple requests for comment. A spokesperson previously spoke out against the bill to ProPublica (搜索), saying the additional requirements would cause "significant costs in exchange for limited return." The group spent over $1 million between January and July on healthcare and generics-related bills, including the Clear Labels Act (搜索), according to its public filings. The trade group for brand-name manufacturers also did not respond to a request for comment; a spokesperson previously said the industry would "welcome conversations about how to strengthen the biopharmaceutical supply chain."
The bill drew pushback from lawmakers on the Senate health committee. Sen. Maggie Hassan, D-N.H., raised the national security concerns, and Paul said he worried about creating an additional hurdle to drug production.